Sight Sciences Stock Earnings Reports

Sight Sciences reported a strong start to 2026 with total Q1 revenue of $19.7M, up 13% year-over-year, driven by Interventional Glaucoma (IG) at $18.3M (+7% YoY) and Interventional Dry Eye (TearCare) at $1.4M (nearly doubling sequentially). The company raised full-year 2026 revenue guidance to $83M–$89M (from $82M–$88M) while reaffirming adjusted operating expense guidance of $93M–$96M. Key operational highlights: OMNI (IG) delivered its third consecutive quarter of year‑over‑year growth, with continued adoption of OMNI Edge and emphasis on expanding combo cataract and stand‑alone markets; TearCare showed early commercial validation in reimbursed markets (notably First Coast and Novitas), selling ~1,500 SmartLids in Q1 and increasing per‑account utilization, with roughly half of active TearCare accounts coming from the existing glaucoma customer base. Gross margin remained strong at 86% (IG 87%, Dry Eye 72%). Adjusted operating expenses declined year-over-year (Q1 adjusted OpEx $21.2M, down 14% YoY) after prior cost reductions. Cash at quarter end was $85M; cash used in Q1 was $7M. Legal update: a final judgment against Alcon affirmed ~ $55M in past damages/interest and 10% ongoing royalties on Hydrus sales, subject to appeal (no cash received to date). Management emphasized disciplined, targeted commercial investments (market access, sales/clinic support) to scale TearCare in reimbursed regions while pursuing additional payer wins in 2026, and reiterated their goal of reaching cash flow breakeven without raising equity.